The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
Open accessAbstract
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson’s disease. We employed a novel, parallel, compound-centric approach to identify a potent and selective LRRK2 inhibitor LRRK2-IN-1, and demonstrated that inhibition of LRRK2 induces dephosphorylation of Ser910/Ser935 and accumulation of LRRK2 within aggregate structures. LRRK2-IN-1 will serve as a versatile tool to pharmacologically interrogate LRRK2 biology and study its role in Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Self-citationWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Cited by
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
Hsieh, C.-H., Shaltouki, A., Gonzalez, A. E., Bettencourt da Cruz, A., Burbulla, L. F., St. Lawrence, E., Schüle, B., Krainc, D., Palmer, T. D., & Wang, X. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.08.002 · Cited by 463
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
Kinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377
Self-citationEnzyme Inhibitor Discovery by Activity-Based Protein Profiling
Niphakis, M. J., & Cravatt, B. F. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035708 · Cited by 366
Herzig, M. C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T. J., Schmid, P., Danner, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr348 · Cited by 360
Sheng, Z., Zhang, S., Bustos, D., Kleinheinz, T., Le Pichon, C. E., Dominguez, S. L., Solanoy, H. O., Drummond, J., Zhang, X., Ding, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004485 · Cited by 353
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2
Liu, G.-H., Qu, J., Suzuki, K., Nivet, E., Li, M., Montserrat, N., Yi, F., Xu, X., Ruiz, S., Zhang, W., et al. (2012) · Nature · doi:10.1038/nature11557 · Cited by 339
LRRK2 Controls an EndoA Phosphorylation Cycle in Synaptic Endocytosis
Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.-J., Morais, V. A., Vilain, S., Haddad, D., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.022 · Cited by 337
WD40 repeat domain proteins: a novel target class?
Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335
Fell, M. J., Mirescu, C., Basu, K., Cheewatrakoolpong, B., DeMong, D. E., Ellis, J. M., Hyde, L. A., Lin, Y., Markgraf, C. G., Mei, H., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227587 · Cited by 305
LRRK2 levels in immune cells are increased in Parkinson’s disease
Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., et al. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-017-0010-8 · Cited by 279
Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease
Martin, I., Kim, J. W., Lee, B. D., Kang, H. C., Xu, J.-C., Jia, H., Stankowski, J., Kim, M.-S., Zhong, J., Kumar, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.064 · Cited by 265
Perera, G., Ranola, M., Rowe, D. B., Halliday, G. M., & Dzamko, N. (2016) · Scientific Reports · doi:10.1038/srep31391 · Cited by 259
Self-citationThe role of the LRRK2 gene in Parkinsonism
Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249
“However, LRRK2-IN1 and CZC-25146 have better selectivity than other kinases for LRRK2 as report recently [117,118].”
BackgroundHenry, A. G., Aghamohammadzadeh, S., Samaroo, H., Chen, Y., Mou, K., Needle, E., & Hirst, W. D. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv314 · Cited by 235
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205
Self-citationHow Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
Bonello, F., Hassoun, S.-M., Mouton-Liger, F., Shin, Y. S., Muscat, A., Tesson, C., Lesage, S., Beart, P. M., Brice, A., Krupp, J., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz004 · Cited by 163
Perspective on the current state of the LRRK2 field
Taymans, J.-M., Fell, M., Greenamyre, T., Hirst, W. D., Mamais, A., Padmanabhan, S., Peter, I., Rideout, H., & Thaler, A. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00544-7 · Cited by 153
Takagawa, T., Kitani, A., Fuss, I., Levine, B., Brant, S. R., Peter, I., Tajima, M., Nakamura, S., & Strober, W. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8162 · Cited by 145
The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease
Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132
LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
Choi, I., Kim, B., Byun, J.-W., Baik, S. H., Huh, Y. H., Kim, J.-H., Mook-Jung, I., Song, W. K., Shin, J.-H., Seo, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms9255 · Cited by 112
LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism
Arranz, A. M., Delbroek, L., Van Kolen, K., Guimarães, M. R., Mandemakers, W., Daneels, G., Matta, S., Calafate, S., Shaban, H., Baatsen, P., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.158196 · Cited by 111
LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients
Atashrazm, F., Hammond, D., Perera, G., Bolliger, M. F., Matar, E., Halliday, G. M., Schüle, B., Lewis, S. J. G., Nichols, R. J., & Dzamko, N. (2019) · Movement Disorders · doi:10.1002/mds.27601 · Cited by 102
Self-citationProgress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Cirnaru, M. D., Marte, A., Belluzzi, E., Russo, I., Gabrielli, M., Longo, F., Arcuri, L., Murru, L., Bubacco, L., Matteoli, M., et al. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00049 · Cited by 93
Marker, D. F., Puccini, J. M., Mockus, T. E., Barbieri, J., Lu, S.-M., & Gelbard, H. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-261 · Cited by 90
Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation
Kuwahara, T., Funakawa, K., Komori, T., Sakurai, M., Yoshii, G., Eguchi, T., Fukuda, M., & Iwatsubo, T. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105081 · Cited by 80
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Kim, J. W., Yin, X., Jhaldiyal, A., Khan, M. R., Martin, I., Xie, Z., Perez-Rosello, T., Kumar, M., Abalde-Atristain, L., Xu, J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.08.002 · Cited by 56
“Two-way ANOVA with Bonferroni post-test (0kcal/mol: inhibitor effect: F=8.17, p<0.01, GS LRRK2 effect: F=10.76, p<0.01, DMSO vs LRRK2-IN-1: ns (Control), p<0.01 (GS LRRK2), DMSO vs CZC-25146: ns (Control), ns (GS LRRK2); −30kcal/mol: inhibitor effect: F=29.08, p<0.001, GS LRRK2 effect: F=44.43, p<0.001, DMSO vs LRRK2-…”
MethodInfluentialVomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5
Gilbert, A. S., Seoane, P. I., Sephton-Clark, P., Bojarczuk, A., Hotham, R., Giurisato, E., Sarhan, A. R., Hillen, A., Velde, G. V., Gray, N. S., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700898 · Cited by 54
Self-citationRAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A
Madero-Pérez, J., Fernández, B., Lara Ordóñez, A. J., Fdez, E., Lobbestael, E., Baekelandt, V., & Hilfiker, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00417 · Cited by 48
Small-Molecule Inhibitors of LRRK2
Hatcher, J. M., Choi, H. G., Alessi, D. R., & Gray, N. S. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_13 · Cited by 39
Self-citationBenzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate
Zaldivar-Diez, J., Li, L., Garcia, A. M., Zhao, W.-N., Medina-Menendez, C., Haggarty, S. J., Gil, C., Morales, A. V., & Martinez, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01752 · Cited by 20
Metadata
- Authors
- Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., & Gray, N. S.
- Venue
- Nature Chemical Biology
- Published
- 2011-03-06
- Volume
- 7
- Issue
- 4
- Pages
- 203-205
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2124681346
- Cited by
- 417
- References
- 24
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.